MCID: CTN007
MIFTS: 62

Cutaneous Leishmaniasis malady

Categories: Infectious diseases

Aliases & Classifications for Cutaneous Leishmaniasis

Aliases & Descriptions for Cutaneous Leishmaniasis:

Name: Cutaneous Leishmaniasis 38 12 14
Asian Desert Cutaneous Leishmaniasis 12 69
Diffuse Cutaneous Leishmaniasis 12 69
Leishmaniasis, Cutaneous 42 69
Ethiopian Cutaneous Leishmaniasis 69
Leishmaniasis Diffuse Cutaneous 52
Leishmaniasis Cutaneous 52
Leproid Leishmaniasis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9111
ICD10 33 B55.1
MeSH 42 D016773
NCIt 47 C34768
SNOMED-CT 64 240637006
UMLS 69 C0023283

Summaries for Cutaneous Leishmaniasis

Disease Ontology : 12 A leishmaniasis that involves skin infection caused by Leishmania species, resulting in one or more cutaneous lesions.

MalaCards based summary : Cutaneous Leishmaniasis, also known as asian desert cutaneous leishmaniasis, is related to lagophthalmos and tuberculosis. An important gene associated with Cutaneous Leishmaniasis is IFNG (Interferon Gamma), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Miconazole and Miltefosine have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are digestive/alimentary and hematopoietic system

Wikipedia : 71 Cutaneous leishmaniasis (also known as oriental sore, tropical sore, chiclero ulcer, chiclero\'s ulcer... more...

Related Diseases for Cutaneous Leishmaniasis

Diseases related to Cutaneous Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
id Related Disease Score Top Affiliating Genes
1 lagophthalmos 29.8 IL10 IL4 TNF
2 tuberculosis 29.5 IL10 IL2 IL4 TNF
3 pulmonary tuberculosis 28.7 IFNG IL10 IL13 IL4 IL5 TLR4
4 leishmaniasis 12.0
5 mucocutaneous leishmaniasis 11.6
6 visceral leishmaniasis 11.3
7 myoglobinuria recurrent 10.3 IFNG IL4
8 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
9 asymptomatic neurosyphilis 10.3 IFNG IL10 IL4
10 tungiasis 10.3 IFNG IL10 IL4
11 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 IL4 TNF
12 conidiobolomycosis 10.3 IL10 IL4 TNF
13 vestibule of mouth cancer 10.3 IL10 IL4 TNF
14 hypotrichosis 4 10.3 IFNG IL4 TNF
15 senile reticular retinal degeneration 10.3 IFNG IL10 TNF
16 conduct disorder 10.3 IFNG IL10 TNF
17 pancreatic signet ring cell adenocarcinoma 10.3 IFNG IL10 TNF
18 pulpitis 10.3 IFNG IL10 TNF
19 transient tic disorder 10.3 IL10 SLC11A1 TNF
20 crustacean allergy 10.3 IFNG IL13 IL4
21 hereditary alpha tryptasemia syndrome 10.3 IFNG IL10 TNF
22 erb-duchenne and dejerine-klumpke palsies 10.3 IFNG IL10 TNF
23 oral cavity cancer 10.3 IFNG IL4 TNF
24 myofibroma 10.3 IFNG IL10 IL13
25 gonococcal endophthalmia 10.3 IL10 IL4 TNF
26 goat milk allergy 10.3 IL10 IL13 IL4
27 sarcomatoid transitional cell carcinoma 10.3 IL10 SLC11A1 TNF
28 tarsal tunnel syndrome 10.3 IL10 IL13 TNF
29 plummer's disease 10.3 IFNG IL10 TNF
30 red cell phospholipid defect with hemolysis 10.3 IFNG IL4 TNF
31 primary ciliary dyskinesia 10.3 IL10 SLC11A1 TNF
32 proximal symphalangism 10.3 IFNG IL10 IL4
33 follicular adenoma 10.3 IFNG IL10 TNF
34 depressed scar 10.2 IFNG IL10 TNF
35 adie pupil 10.2 FCER2 IL4
36 burns 10.2 IFNG IL10 TNF
37 leukoplakia of penis 10.2 IL10 IL4 TLR2
38 status epilepticus 10.2 IFNG IL4 TNF
39 classic type lipoma 10.2 IFNG IL10 TNF
40 nystagmus, congenital motor, autosomal recessive 10.2 SLC11A1 TLR2 TNF
41 vulvar nodular hidradenoma 10.2 IFNG IL10 TNF
42 anal atresia, hypospadias, and penoscrotal inversion 10.2 IFNG SLC11A1 TLR2
43 osteodysplasty precocious of danks mayne and kozlowski 10.2 IFNG IL10 IL4 TNF
44 neurotic disorder 10.2 IFNG IL10 IL4 TNF
45 ectodermal dysplasia bartalos type 10.2 IFNG IL10 IL4 TNF
46 centronuclear myopathy 5 10.2 IFNG IL10 IL4 SLC11A1
47 motor peripheral neuropathy 10.2 IFNG IL10 IL4 TNF
48 atrophy of prostate 10.2 IL10 TLR2 TNF
49 steatitis 10.2 IL2 TNF
50 esophageal candidiasis 10.2 IFNG IL10 IL4 TNF

Graphical network of the top 20 diseases related to Cutaneous Leishmaniasis:



Diseases related to Cutaneous Leishmaniasis

Symptoms & Phenotypes for Cutaneous Leishmaniasis

MGI Mouse Phenotypes related to Cutaneous Leishmaniasis:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.33 FCER2 FOXP3 IFNG IL10 IL13 IL2
2 hematopoietic system MP:0005397 10.32 FCER2 FOXP3 GPI IFNG IL10 IL13
3 cellular MP:0005384 10.3 IL10 IL13 IL2 IL4 MPI TLR2
4 growth/size/body region MP:0005378 10.3 FOXP3 GPI IFNG IL10 IL13 IL2
5 immune system MP:0005387 10.29 FCER2 FOXP3 GPI IFNG IL10 IL13
6 homeostasis/metabolism MP:0005376 10.27 FOXP3 GPI IFNG IL10 IL13 IL2
7 cardiovascular system MP:0005385 10.22 FOXP3 GPI IFNG IL10 IL2 MPI
8 mortality/aging MP:0010768 10.22 MPI SLC11A1 TLR2 TLR4 TNF FCER2
9 endocrine/exocrine gland MP:0005379 10.14 IL10 IL13 IL2 IL4 TLR2 TNF
10 liver/biliary system MP:0005370 10.13 IL4 IL5 TLR2 TLR4 TNF FOXP3
11 integument MP:0010771 10.06 FOXP3 IFNG IL10 IL13 IL4 TLR2
12 neoplasm MP:0002006 9.97 IFNG IL10 IL2 IL5 SLC11A1 TLR2
13 no phenotypic analysis MP:0003012 9.92 FOXP3 GPI IFNG IL10 IL13 IL2
14 reproductive system MP:0005389 9.91 TNF FOXP3 IFNG IL10 IL13 IL2
15 respiratory system MP:0005388 9.9 FOXP3 GPI IFNG IL10 IL13 IL2
16 skeleton MP:0005390 9.61 IFNG IL10 IL13 IL4 MPI PGD
17 vision/eye MP:0005391 9.17 FOXP3 IFNG IL10 IL2 IL4 TLR4

Drugs & Therapeutics for Cutaneous Leishmaniasis

Drugs for Cutaneous Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Miltefosine Approved Phase 4,Phase 3,Phase 2 58066-85-6 3600
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
4 meglumine antimoniate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Anthelmintics Phase 4,Phase 2,Phase 1
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antimony Sodium Gluconate Phase 4,Phase 2,Phase 1
9 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Anesthetics Phase 4
12
Nitric Oxide Approved Phase 3 10102-43-9 145068
13
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
14
Imiquimod Approved, Investigational Phase 3,Phase 2 99011-02-6 57469
15
Pentamidine Approved Phase 2, Phase 3 100-33-4 4735
16
Paromomycin Approved, Investigational Phase 3,Phase 2,Early Phase 1 1263-89-4, 7542-37-2 165580
17
Fluconazole Approved Phase 3 86386-73-4 3365
18
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 53477736 447043
19
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
20 interferons Phase 3,Phase 2
21 Adjuvants, Immunologic Phase 2, Phase 3, Phase 1
22 Neurotransmitter Agents Phase 3,Phase 2
23 Gentamicins Phase 3,Phase 2
24 Aluminum sulfate Phase 2, Phase 3, Phase 1
25 Vaccines Phase 2, Phase 3, Phase 1
26 Peripheral Nervous System Agents Phase 3
27 Vasodilator Agents Phase 2, Phase 3
28 Endothelium-Dependent Relaxing Factors Phase 3
29 Anti-Asthmatic Agents Phase 3
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Phosphodiesterase Inhibitors Phase 2, Phase 3
32 Platelet Aggregation Inhibitors Phase 2, Phase 3
33 Protective Agents Phase 2, Phase 3
34 Interferon Inducers Phase 3,Phase 2
35 Radiation-Protective Agents Phase 2, Phase 3
36 Respiratory System Agents Phase 3
37 Antibiotics, Antitubercular Phase 3,Phase 2
38 Autonomic Agents Phase 3
39 Bronchodilator Agents Phase 3
40 Antioxidants Phase 2, Phase 3
41 Tocopherols Phase 3
42 Tocotrienols Phase 3
43 Vitamins Phase 3
44 Steroid Synthesis Inhibitors Phase 3
45 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
46 Cytochrome P-450 Enzyme Inhibitors Phase 3
47 Hormone Antagonists Phase 3
48 Hormones Phase 3
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
50 Tocopherol Nutraceutical Phase 3

Interventional clinical trials:

(show top 50) (show all 84)
id Name Status NCT ID Phase
1 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4
2 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4
3 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4
4 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4
5 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4
6 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3
7 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3
8 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3
9 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3
10 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3
11 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3
12 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3
13 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3
14 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3
15 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
16 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
17 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3
18 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3
19 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3
20 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Active, not recruiting NCT01301924 Phase 2, Phase 3
21 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3
22 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Not yet recruiting NCT03096457 Phase 2, Phase 3
23 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3
24 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3
25 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3
26 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
27 Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia Unknown status NCT00537953 Phase 2
28 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01083576 Phase 2
29 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Completed NCT00703924 Phase 2
30 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) Completed NCT01032382 Phase 2
31 Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil) Completed NCT00600548 Phase 2
32 WR 279,396 for the Treatment of Cutaneous Leishmaniasis Completed NCT01988909 Phase 2
33 Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia Completed NCT01845727 Phase 1, Phase 2
34 Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis Completed NCT00973128 Phase 2
35 Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis Completed NCT02919605 Phase 2
36 Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Completed NCT00233545 Phase 2
37 Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis Completed NCT01380314 Phase 2
38 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis Completed NCT00884377 Phase 2
39 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis Completed NCT01011309 Phase 2
40 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis Completed NCT01536795 Phase 2
41 Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Completed NCT01300975 Phase 2
42 Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Completed NCT00004755 Phase 2
43 Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 Completed NCT00657917 Phase 2
44 Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients Completed NCT00996463 Phase 2
45 Miltefosine to Treat Mucocutaneous Leishmaniasis Completed NCT01050907 Phase 2
46 Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite Completed NCT00121862 Phase 2
47 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen Completed NCT00633009 Phase 2
48 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2
49 Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Completed NCT01377974 Phase 2
50 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2

Search NIH Clinical Center for Cutaneous Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leishmaniasis, cutaneous

Genetic Tests for Cutaneous Leishmaniasis

Anatomical Context for Cutaneous Leishmaniasis

MalaCards organs/tissues related to Cutaneous Leishmaniasis:

39
Skin, T Cells, Testes, Monocytes, Neutrophil, Thyroid, Placenta

Publications for Cutaneous Leishmaniasis

Articles related to Cutaneous Leishmaniasis:

(show top 50) (show all 735)
id Title Authors Year
1
Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis. ( 27986151 )
2017
2
SLC11A1 polymorphisms and host susceptibility to cutaneous leishmaniasis in Pakistan. ( 28061874 )
2017
3
First description of Leishmania (Viannia) infection in Evandromyia saulensis, Pressatia sp. and Trichophoromyia auraensis (Psychodidae: Phlebotominae) in a transmission area of cutaneous leishmaniasis in Acre state, Amazon Basin, Brazil. ( 28076470 )
2017
4
Aspects on the Ecology of Phlebotomine Sand Flies (Diptera: Psychodidae) From GuaraA-, State of Tocantins, Brazil, Endemic Area for American Cutaneous Leishmaniasis. ( 28082651 )
2017
5
The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. ( 28043177 )
2017
6
Reprint of "Spatial modeling of Cutaneous Leishmaniasis in Iran from 1983 to 2013". ( 27914666 )
2017
7
Sporothrix schenckii Sensu Lato identification in fragments of skin lesion cultured in NNN medium for differential diagnosis of cutaneous leishmaniasis. ( 27914747 )
2017
8
The new situation of cutaneous leishmaniasis after Syrian civil war in Gaziantep city, Southeastern region of Turkey. ( 27983970 )
2017
9
A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions. ( 27148363 )
2016
10
Effective treatment of cutaneous leishmaniasis caused by Leishmania tropica with topical photodynamic therapy. ( 27509427 )
2016
11
Spatial Analyses of the Relation between Rodent's Active Burrows and Incidence of Zoonotic Cutaneous Leishmaniasis in Golestan Province, Northeastern of Iran. ( 28032109 )
2016
12
Molecular Epidemiological Survey of Cutaneous Leishmaniasis in Two Highly Endemic Metropolises of Iran, Application of FTA Cards for DNA Extraction From Giemsa-Stained Slides. ( 27127596 )
2016
13
A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations. ( 27109311 )
2016
14
Epidemiologic profile of oriental sore caused by Leishmania parasites in a new endemic focus of cutaneous leishmaniasis, southern Iran. ( 27605840 )
2016
15
Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in Mice. ( 27632901 )
2016
16
Faunal Distribution and Seasonal Bio-Ecology of Naturally Infected Sand Flies in a New Endemic Zoonotic Cutaneous Leishmaniasis Focus of Southern Iran. ( 28032108 )
2016
17
Correlation of Genetic Heterogeneity with Cytopathological and Epidemiological Findings of Leishmania major Isolated from Cutaneous Leishmaniasis in Southern Iran. ( 27215312 )
2016
18
Cutaneous Leishmaniasis: The Truth about the 'Flesh-Eating Disease' in Syria. ( 27105932 )
2016
19
Pediatric Dermatology Photoquiz: Refractory Purulent Paronychia in a Young Girl. Paronychial cutaneous leishmaniasis. ( 26758096 )
2016
20
Frequency of Cutaneous Leishmaniasis and Species Identification in Suspected Individuals from Golestan Province, Northern Iran in 2014. ( 27957442 )
2016
21
Intralesional Versus Oral Chloroquine in Cutaneous Leishmaniasis: Comparison of Outcome, Duration of Treatment and Total Dose of Drug. ( 27097693 )
2016
22
Therapeutic Effect of Scrophularia striata Ethanolic Extract against Localized Cutaneous Leishmaniasis Caused by Leishmania major (MRHO/IR/75/ER). ( 27957441 )
2016
23
Amiodarone triggers induction of apoptosis in cutaneous leishmaniasis agents. ( 27553974 )
2016
24
Disseminated cutaneous leishmaniasis: ulcerovegetative and ulcero-crusted lesions. ( 28012931 )
2016
25
Correction: Down-Regulation of TLR and JAK/STAT Pathway Genes Is Associated with Diffuse Cutaneous Leishmaniasis: A Gene Expression Analysis in NK Cells from Patients Infected with Leishmania Mexicana. ( 27096541 )
2016
26
Identification of Leishmania Species Isolated from Human Cutaneous Leishmaniasis in Mehran, Western Iran Using Nested PCR. ( 27095970 )
2016
27
Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole. ( 27549634 )
2016
28
Panniculitis is a common unrecognized histopathological feature of cutaneous leishmaniasis. ( 26960628 )
2016
29
Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis. ( 28001228 )
2016
30
Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. ( 27508321 )
2016
31
NRAMP1 Polymorphisms like Susceptibility Marker in Mexican Focus of Cutaneous Leishmaniasis. ( 27830154 )
2016
32
Cutaneous leishmaniasis: An opportunistic infection. ( 27642092 )
2016
33
Risk Mapping and Situational Analysis of Cutaneous Leishmaniasis in an Endemic Area of Central Iran: A GIS-Based Survey. ( 27574805 )
2016
34
The sesquiterpene (-)-I+-bisabolol is active against the causative agents of Old World cutaneous leishmaniasis through the induction of mitochondrial-dependent apoptosis. ( 27539477 )
2016
35
Ecological Niche Modeling of main reservoir hosts of zoonotic cutaneous leishmaniasis in Iran. ( 27150212 )
2016
36
Cutaneous Leishmaniasis Vaccination: A Matter of Quality. ( 27148270 )
2016
37
Predicting the Distribution of Phlebotomus papatasi (Diptera: Psychodidae), the Primary Vector of Zoonotic Cutaneous Leishmaniasis, in Golestan Province of Iran Using Ecological Niche Modeling: Comparison of MaxEnt and GARP Models. ( 28025245 )
2016
38
Genetic micro-heterogeneity of Leishmania major in emerging foci of zoonotic cutaneous leishmaniasis in Tunisia. ( 27137082 )
2016
39
Characterization of Neutrophil Function in Human Cutaneous Leishmaniasis Caused by Leishmania braziliensis. ( 27167379 )
2016
40
Detection of IgG Anti-Leishmania Antigen by Flow Cytometry as a Diagnostic Test for Cutaneous Leishmaniasis. ( 27622535 )
2016
41
Evaluation of different diagnostic methods of American Cutaneous Leishmaniasis in the Brazilian Amazon. ( 27119738 )
2016
42
Aspects on the Ecology of Phlebotomine Sand Flies (Diptera: Psychodidae) From GuaraA-, State of Tocantins, Brazil, Endemic Area for American Cutaneous Leishmaniasis. ( 27590233 )
2016
43
Antileishmanial activity of ezetimibe: inhibition of sterol biosynthesis, in vitro synergy with azoles and efficacious in experimental cutaneous leishmaniasis. ( 27600041 )
2016
44
Clinical study of cutaneous leishmaniasis in the Kashmir Valley. ( 27990396 )
2016
45
Cutaneous Leishmaniasis in Khyber Pakhtunkhwa Province of Pakistan: Clinical Diversity and Species-Level Diagnosis. ( 27601518 )
2016
46
Cutaneous Leishmaniasis and Conflict in Syria. ( 27088251 )
2016
47
NRAMP1 gene polymorphisms and cutaneous leishmaniasis: An evaluation on host susceptibility and treatment outcome. ( 27681549 )
2016
48
RISK FACTORS ASSOCIATED WITH AMERICAN CUTANEOUS LEISHMANIASIS IN AN ENDEMIC AREA OF BRAZIL. ( 27982352 )
2016
49
Real-time PCR using FRET technology for Old World cutaneous leishmaniasis species differentiation. ( 27141967 )
2016
50
Pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis. ( 27956421 )
2016

Variations for Cutaneous Leishmaniasis

Expression for Cutaneous Leishmaniasis

LifeMap Discovery
Genes differentially expressed in tissues of Cutaneous Leishmaniasis patients vs. healthy controls: 35 (show top 50) (show all 174)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL9 chemokine (C-X-C motif) ligand 9 Skin + 6.42 0.000
2 CXCL10 chemokine (C-X-C motif) ligand 10 Skin + 6.16 0.000
3 IDO1 indoleamine 2,3-dioxygenase 1 Skin + 5.97 0.000
4 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) Skin + 5.88 0.000
5 GBP5 guanylate binding protein 5 Skin + 5.82 0.000
6 PIP prolactin-induced protein Skin - 5.80 0.000
7 GNLY granulysin Skin + 5.77 0.000
8 MMP1 matrix metallopeptidase 1 Skin + 5.47 0.000
9 DCD dermcidin Skin - 5.36 0.000
10 GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) Skin + 5.30 0.000
11 SCGB1D2 secretoglobin, family 1D, member 2 Skin - 5.14 0.000
12 CCL8 chemokine (C-C motif) ligand 8 Skin + 5.01 0.000
13 NKG7 natural killer cell granule protein 7 Skin + 4.99 0.000
14 GZMK granzyme K (granzyme 3; tryptase II) Skin + 4.89 0.000
15 SCGB2A2 secretoglobin, family 2A, member 2 Skin - 4.87 0.000
16 IGLL1 immunoglobulin lambda-like polypeptide 1 Skin + 4.82 0.000
17 CCL5 chemokine (C-C motif) ligand 5 Skin + 4.78 0.000
18 MMP3 matrix metallopeptidase 3 Skin + 4.69 0.000
19 CCL3L3 chemokine (C-C motif) ligand 3-like 3 Skin + 4.67 0.000
20 UBD ubiquitin D Skin + 4.67 0.000
21 ADAMDEC1 ADAM-like, decysin 1 Skin + 4.65 0.000
22 EPSTI1 epithelial stromal interaction 1 (breast) Skin + 4.53 0.000
23 JCHAIN joining chain of multimeric IgA and IgM Skin + 4.53 0.000
24 C5orf46 chromosome 5 open reading frame 46 Skin - 4.53 0.000
25 C1QB complement component 1, q subcomponent, B chain Skin + 4.51 0.000
26 GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) Skin + 4.48 0.000
27 GBP1 guanylate binding protein 1, interferon-inducible Skin + 4.45 0.000
28 CCL4L1 chemokine (C-C motif) ligand 4-like 1 Skin + 4.44 0.000
29 MED27 mediator complex subunit 27 Skin - 4.31 0.000
30 FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide Skin + 4.29 0.000
31 KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 Skin + 4.27 0.000
32 SERPINA12 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12 Skin - 4.25 0.000
33 GBP4 guanylate binding protein 4 Skin + 4.23 0.000
34 CD8A CD8a molecule Skin + 4.23 0.000
35 TDO2 tryptophan 2,3-dioxygenase Skin + 4.19 0.000
36 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) Skin + 4.17 0.000
37 CXCL8 chemokine (C-X-C motif) ligand 8 Skin + 4.13 0.000
38 KRT27 keratin 27, type I Skin - 4.13 0.000
39 DAPL1 death associated protein-like 1 Skin - 4.10 0.000
40 LYZ lysozyme Skin + 4.10 0.000
41 THRSP thyroid hormone responsive Skin - 4.06 0.000
42 CHP2 calcineurin-like EF-hand protein 2 Skin - 4.03 0.000
43 PRF1 perforin 1 (pore forming protein) Skin + 4.03 0.000
44 LAG3 lymphocyte-activation gene 3 Skin + 3.99 0.000
45 CYBB cytochrome b-245, beta polypeptide Skin + 3.98 0.000
46 WARS tryptophanyl-tRNA synthetase Skin + 3.98 0.000
47 CD3D CD3d molecule, delta (CD3-TCR complex) Skin + 3.97 0.000
48 IL18BP interleukin 18 binding protein Skin + 3.96 0.000
49 SNX10 sorting nexin 10 Skin + 3.96 0.000
50 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 Skin + 3.95 0.000
Search GEO for disease gene expression data for Cutaneous Leishmaniasis.

Pathways for Cutaneous Leishmaniasis

Pathways related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 FCER2 GPI IFNG IL10 IL13 IL2
2
Show member pathways
13.68 FCER2 IFNG IL10 IL13 IL2 IL4
3
Show member pathways
13.44 IL10 IL13 IL2 IL4 IL5 TLR2
4
Show member pathways
13.39 FCER2 IFNG IL10 IL13 IL2 IL4
5
Show member pathways
13.23 FCER2 IFNG IL2 IL4 TLR2 TLR4
6
Show member pathways
12.95 IFNG IL10 IL2 TLR2 TLR4 TNF
7
Show member pathways
12.89 FOXP3 IFNG IL10 IL13 IL2 IL4
8
Show member pathways
12.87 IFNG IL13 IL2 IL4 TLR2 TLR4
9
Show member pathways
12.66 IFNG IL10 IL2 IL4 TNF
10 12.6 FOXP3 IFNG IL10 IL2 IL4 TLR2
11
Show member pathways
12.51 IFNG IL2 IL4 TNF
12
Show member pathways
12.51 IFNG IL10 IL2 IL4 IL5 TNF
13
Show member pathways
12.41 IFNG IL13 IL4 IL5 TLR2 TNF
14
Show member pathways
12.39 FOXP3 IFNG IL10 IL13 IL2 IL4
15
Show member pathways
12.35 IFNG IL2 IL4 TNF
16
Show member pathways
12.33 IFNG IL10 IL4 TLR2 TLR4 TNF
17 12.31 IFNG IL10 TLR2 TLR4 TNF
18
Show member pathways
12.28 IFNG IL10 IL13 IL2 IL4 IL5
19
Show member pathways
12.26 IFNG IL4 TLR2 TLR4 TNF
20 12.22 IFNG TLR2 TLR4 TNF
21
Show member pathways
12.16 IFNG IL10 IL13 IL2 IL4 IL5
22
Show member pathways
12.12 IL13 IL2 IL5 TLR2 TLR4
23 12.1 IFNG IL2 IL4 TLR4 TNF
24 12.07 FCER2 IL10 IL13 IL4 TNF
25 12.06 IFNG IL10 IL2 IL4 IL5 TNF
26
Show member pathways
12 IFNG IL10 IL2 TLR2 TLR4 TNF
27
Show member pathways
11.99 IFNG IL4 TLR2 TLR4
28 11.99 IFNG IL10 TLR2 TLR4 TNF
29
Show member pathways
11.96 IFNG IL2 IL4
30 11.96 FCER2 IL4 IL5 TNF
31 11.92 IFNG TLR2 TLR4 TNF
32 11.9 IFNG IL13 IL2 IL4 IL5
33 11.85 IFNG IL10 IL2 TNF
34 11.83 FCER2 TLR2 TLR4
35 11.82 IFNG IL10 IL13 IL2 IL4 IL5
36
Show member pathways
11.79 FOXP3 IFNG IL2 IL4 IL5 TNF
37 11.78 IL10 TLR4 TNF
38 11.76 FCER2 IL10 IL4 IL5
39 11.75 IL13 IL4 IL5 TNF
40
Show member pathways
11.72 FOXP3 IL2 IL4
41 11.72 IFNG IL10 IL2
42 11.71 FOXP3 IL10 IL4 IL5 TLR2 TLR4
43
Show member pathways
11.69 IFNG IL2 TNF
44
Show member pathways
11.68 IFNG IL2 TNF
45 11.63 TLR2 TLR4 TNF
46 11.62 IFNG TLR2 TLR4 TNF
47 11.62 FCER2 IL10 IL13 IL4 TNF
48 11.61 IFNG IL10 TLR2 TLR4 TNF
49 11.59 IFNG IL2 TNF
50 11.56 IFNG IL2 TNF

GO Terms for Cutaneous Leishmaniasis

Cellular components related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 FCER2 GPI IFNG IL10 IL13 IL2
2 extracellular space GO:0005615 9.56 GPI IFNG IL10 IL13 IL2 IL4
3 external side of plasma membrane GO:0009897 9.1 FCER2 IFNG IL13 IL4 TLR4 TNF

Biological processes related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
id Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.99 IFNG IL10 SLC11A1 TLR4 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.97 IFNG IL2 IL4 TNF
3 response to lipopolysaccharide GO:0032496 9.97 IL10 IL13 SLC11A1 TLR2 TLR4
4 inflammatory response GO:0006954 9.95 IL10 IL13 IL5 SLC11A1 TLR2 TLR4
5 cellular response to lipopolysaccharide GO:0071222 9.94 IFNG IL10 TLR4 TNF
6 response to virus GO:0009615 9.92 FOXP3 IFNG TNF
7 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.92 IL10 IL4 IL5 TNF
8 negative regulation of inflammatory response GO:0050728 9.9 FOXP3 IL10 IL2
9 positive regulation of T cell proliferation GO:0042102 9.89 IFNG IL2 IL4
10 positive regulation of inflammatory response GO:0050729 9.89 IL2 TLR2 TLR4
11 humoral immune response GO:0006959 9.89 GPI IFNG TNF
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 IFNG IL2 IL4
13 positive regulation of tumor necrosis factor production GO:0032760 9.87 IFNG TLR2 TLR4
14 positive regulation of interleukin-6 production GO:0032755 9.87 TLR2 TLR4 TNF
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 IFNG TLR4 TNF
16 negative regulation of tumor necrosis factor production GO:0032720 9.84 FOXP3 IL10 TLR4
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.82 TLR2 TLR4 TNF
18 negative regulation of endothelial cell apoptotic process GO:2000352 9.81 IL10 IL13 IL4
19 negative regulation of interferon-gamma production GO:0032689 9.8 FOXP3 IL10 TLR4
20 positive regulation of interleukin-8 production GO:0032757 9.8 TLR2 TLR4 TNF
21 positive regulation of interleukin-12 production GO:0032735 9.79 IFNG TLR2 TLR4
22 positive regulation of interleukin-10 production GO:0032733 9.78 IL4 TLR2 TLR4
23 positive regulation of NF-kappaB import into nucleus GO:0042346 9.77 TLR2 TLR4 TNF
24 positive regulation of chemokine production GO:0032722 9.76 TLR2 TLR4 TNF
25 positive regulation of interferon-gamma production GO:0032729 9.76 IL2 SLC11A1 TLR4 TNF
26 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.75 IL2 IL4
27 negative regulation of growth of symbiont in host GO:0044130 9.75 IFNG IL10 TNF
28 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.74 IL10 TNF
29 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 IFNG TNF
30 negative regulation of nitric oxide biosynthetic process GO:0045019 9.74 IL10 IL4
31 response to molecule of bacterial origin GO:0002237 9.74 IL10 TLR2
32 positive regulation of macrophage activation GO:0043032 9.74 IL10 IL13
33 I-kappaB phosphorylation GO:0007252 9.74 TLR2 TLR4
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 IL10 TNF
35 positive regulation of podosome assembly GO:0071803 9.73 IL5 TNF
36 regulation of cytokine secretion GO:0050707 9.73 TLR2 TLR4
37 positive regulation of regulatory T cell differentiation GO:0045591 9.73 FOXP3 IL2
38 macrophage activation GO:0042116 9.73 SLC11A1 TLR4
39 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.73 FCER2 TLR2 TLR4
40 positive regulation of mast cell degranulation GO:0043306 9.72 IL13 IL4
41 cellular response to lipoteichoic acid GO:0071223 9.72 TLR2 TLR4
42 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.72 TLR4 TNF
43 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
44 microglial cell activation GO:0001774 9.72 IL13 IL4 TLR2
45 positive regulation of immunoglobulin production GO:0002639 9.71 IL13 IL4
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 IL10 TNF
47 negative regulation of lymphocyte proliferation GO:0050672 9.71 FOXP3 IL2
48 positive regulation of immunoglobulin secretion GO:0051024 9.71 GPI IL2 IL5
49 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.7 IFNG TLR4
50 type 2 immune response GO:0042092 9.7 IL10 IL4

Molecular functions related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 GPI IL10 IL2 IL4 IL5
2 cytokine activity GO:0005125 9.23 GPI IFNG IL10 IL13 IL2 IL4
3 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4

Sources for Cutaneous Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....